Home > Back to Publisher > Report Information

Conference Documentation: In Vitro Diagnostics (2010)

SMI Publishing, Ltd
July 12, 2010
SKU: SMI2779907

Abstract Table of Contents Related Reports

According to a recent Frost & Sullivan report, "The global IVD market has shown a consistent growth of 6.72 percent annually, a trend that is expected to continue until 2012."

The IVD market remains to be one of the most promising markets in the world.

SMi's 2nd annual In Vitro Diagnostics conference will provide an integral forum to leaders in biotech, pharma and labs to discuss the value of diagnostics and overcome challenges posed by regulatory bodies. Make sure you attend this event and successfully align your business strategies for potential opportunities.

DAY 1
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks: David Huckle, Chief Executive, Adams Business Associates.
9.10 ANALYSING KEY IVD MARKET DRIVERS: Impact on growth of Regulations, Reimbursement & Health Technology Assessment; Newly developed markets; IVD market forecasts in a recessionary economy; David Huckle, Chief Executive, Adams Business Associates.
9.50 EMERGING TRENDS IN IMMUNO AND MOLECULAR DIAGNOSTICS: Molecular diagnostics in personalised medicine; Companion Diagnostics; Future trends; Eddie Blair, Director, Integrated Medicines Ltd.
10.30 Morning Coffee
10.50 DELIVERING ON THE PROMISE OF PERSONALIZED HEALTHCARE: Overview of Personalized Healthcare; Challenges across the value chain; Examples from AstraZeneca; Ansar Jawaid, Global Diagnostics Manager, AstraZeneca.
11.30 UNDERSTANDING THE ROLE AND IMPACT OF NEW TECHNOLOGIES IN POINT OF CARE TESTING: Technology Review - Current status; Technology Review - Developing and Future Technologies.; Pathway changes & affect on Implementation; Role of Health Technology Assessment (HTA); Anthony James, Technology Adoption Associate, NHS Institute for Innovation and Improvement.
12.10 A NEW ACCURATE AND ROBUST, PCR, PROPRIETARY MOLECULAR BIOLOGY METHOD FOR MULTIPLEX DIAGNOSTICS: Method has potential to detect any bacteria, mycobacteria or fungi; Can resolve up to 2 to the power 10 = 1024 bacterial types in one well; Can return up results in up to 2 hours; UK Government SMART Award winning technology; Ray Harrison, Chief Executive Officer, Point-2-Point Genomics Ltd.
12.30 PRICING AND REIMBURSEMENT STRATEGY FOR IN VITRO DIAGNOSTICS: Common pitfalls in P&R for in vitro diagnostics; Profiling the product's clinical and economic value is a key requirement; A structured approach to developing the optimal P&R strategy; International dimension of the P&R strategy; Gerald Schnell , Partner, Simon-Kucher & Partners.
1.10 Networking Lunch
2.10 DRIVERS OF SUPPLY & DEMAND FOR DIAGNOSTICS: Diagnostics for health checks- the need for POCT; Problems in the past- re quality/technology etc; Current Situation; What more we need under future; Devaki Nair, Consultant Clinical Pathologist, Royal Free Hospital.
2.50 CLINICALLY USEFUL POINT-OF-CARE DIAGNOSTICS FOR INFECTIOUS DISEASES: The Technology Strategy Board’s Innovation Platform on the Detection & Identification of Infectious Agents; Why Point-of-Care? Challenges and opportunities; Emerging technologies and capabilities; Penny Wilson, Lead Specialist, Detection and Identification Of Infectious Agents, Technology Strategy Board.
3.30 Afternoon Tea
3.50 IVD INDUSTRY GUIDELINES, STUDY DESIGN & ANALYSIS CONSIDERATIONS: References and guidelines to follow during research & development; Critical experimental design considerations not necessarily addressed in guidelines; Common study design and data analysis mistakes; Vicki Petrides, Statistician Section Head, Diagnostics Division, Abbott .
4.30 THE PROCESS OF MARKET SURVEILLANCE AND AUDITING: Post market surveillance of IVDs; Vigilance MEDDEV; Compliance issues; Elaine Mooney, Scientific Officer IVD’s, Irish Medicines Board.
5.10 Chairman’s Closing Remarks and Close of Day One
DAY 2
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks: David Huckle, Chief Executive, Adams Business Associates.
9.10 FUTURE OF DIAGNOSTIC TESTS IN CLINICAL PRACTICE FOR PERSONALIZED MEDICINE: Current and future status of in vivo and in vitro tests as point of care diagnostic tools; Future of non invasive breath tests in personalized medicine.; Companion diagnostic tests for individualized therapy.; Challenges in getting diagnostic tests into routine clinical practice; Anil Modak, Associate Director, Medical Products Research & Development, Cambridge Isotope Laboratories Inc..
9.50 HOW DO PHARMA/BIOTECH COMPANIES ACQUIRE PERSONALISED MEDICINE TECHNOLOGIES: Deal trends in pharma/biotech - where do biomarkers and diagnostics fit in?; Strategies and business models; Success stories and the future; Adrian Dawkes, Senior Director, Pharma Ventures.
10.30 APPLYING MICROFLUIDICS TO ENABLE POINT-OF-CARE IMMUNODIAGNOSTICS: Integration of typical assay steps; Cost efficient production of Biochips; Rapid assay results with high sensitivity; Holger Bartos, Director of Marketing and Sales, Boehringer Ingelheim Microparts Gmbh.
11.10 Morning Coffee
11.30 THE INTRODUCTION OF DIAGNOSTICS FOR PERSONALISED MEDICINE IN THE UK NATIONAL HEALTH SERVICE: An overview of UK National Health Service biomedical diagnostics; How the NHS introduces new molecular genetic testing services; Examples of NHS delivery of personalized medicine diagnostics; Rob Elles, Director of Molecular Genetics, National Genetics Reference Lab, Manchester.
12.10 OPPORTUNITIES FOR NEW BIOCHIP TECHNOLOGY IN LABORATORY & POINT OF CARE TESTING: Biochips for infectious disease stratification and therapy selection; Importance of pathogen, drug and host for diagnostics; Rapid pathogen and antibiotic resistance testing; Till Bachmann, COO, Head of Biochip Research, University of Edinburgh.
12.50 Networking Lunch
1.50 IMPROVING MOLECULAR DIAGNOSTICS THROUGH BIOCHIPS AND NANOTECHNOLOGY: Gene investigation in R&D and clinical molecular diagnostics; Pre-implantation genetic diagnosis; Post and prenatal diagnosis; Future of micro arrays and nanotechnology; Moncef Benkhalifa, Director, ATL R&D, Unilabs France.
2.30 FROM EARLY DEVELOPMENT TO PROOF OF CONCEPT: KEY ASPECTS OF THE POC STUDY: Strategic aspects; Is it possible to combine PoC with first in man (FiM) studies?; What is the optimal time point to perform a PoC-study?; Implementing a PoC (point of care test) into a PoC-study; Michael-Friedrich Boettcher, Study Manager and Coordinator, Bayer A G.
3.10 EMERGENCE OF NON TRADITIONAL STAKEHOLDERS IN THE IVD INDUSTRY: In vitro diagnostics is seeing a dramatic increase in the number of stakeholders actively engaging in promoting and furthering its use in the delivery of healthcare for patients; In addition to traditional stakeholders such as regulator, payors, physicians, lab directors, and patients a new set of stakeholders are emerging to influence the industry; Pharmaceutical companies, Pharmacy Benefit Managers, Health IT companies, and Life Science Tools companies are some key emerging stakeholders that are expected to have a dramatic impact on the industry; Harry Glorikian, Managing Partner, Scientia Advisors.
3.50 Chairman’s Closing Remarks and Afternoon Tea
4.00 Close of Conference

Conference Documentation: In Vitro Diagnostics (2010)

Share this report

Other tasks

Research Assistance

Related Markets

General In Vitro Diagnostics Reports

Free Alert Me service